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Purpose:

To quantitatively evaluate a small pilot group of ex-smokers
with chronic obstructive pulmonary disease (COPD) and
healthy volunteers during approximately 2 years by using
hyperpolarized helium 3 (3He) magnetic resonance (MR)
imaging.

Materials and
Methods:

All subjects provided written informed consent to the study
protocol, which was approved by the local research ethics
board and Health Canada and was compliant with the Personal Information Protection and Electronic Documents
Act and HIPAA. Hyperpolarized 3He MR imaging, hydrogen 1 MR imaging, spirometry, and plethysmography were
performed in 15 ex-smokers with COPD and five healthy
volunteers (with the same mean age and age range) at
baseline and 26 months 6 2 (standard deviation) later.
Apparent diffusion coefficients (ADCs) derived from 3He
MR imaging were calculated from diffusion-weighted 3He
MR images, and 3He ventilation defect volume (VDV) and
ventilation defect percentage (VDP) were generated after
manual segmentation of 3He MR spin-density images.

Results:

For subjects with COPD, significant increases in 3He MR
imaging–derived VDV (P = .03), VDP (P = .006), and
ADC (P = .02) were detected, whereas there was no significant change in forced expiratory volume in 1 second
(FEV1) (P = .97). For healthy never-smokers, there was
no significant change in imaging or pulmonary function
measurements at follow-up. There was a significant correlation between changes in FEV1 and changes in VDV
(r = 20.70, P = .02) and VDP (r = 20.70, P = .03).

Conclusion:

For this small pilot group of ex-smokers with COPD, 3He
MR imaging–derived VDV, VDP, and ADC measurements
worsened significantly, but there was no significant change
in FEV1, suggesting increased sensitivity of hyperpolarized
3
He MR imaging for depicting COPD changes during short
time periods.
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hronic obstructive pulmonary disease (COPD) is a leading cause
of morbidity and mortality and affects at least 600 million people worldwide (1). It is the world’s fourth leading
cause of death and the most common
chronic, terminal respiratory disease
(2). Because of the heterogeneous nature of COPD, studies of its natural history and progression are complex, typically requiring large-study sample sizes
and long durations to obtain relevant
longitudinal end points. Accordingly,
much of our current understanding of
the natural history of COPD arises from
the landmark study of Fletcher and
Peto (3) and is based on cross-sectional
spirometric measurements of forced
expiratory volume in 1 second (FEV1).
The current functional definition of
COPD (4) is also based on FEV1, and
change in FEV1 over the course of time
is still the most widely accepted measure of COPD progression. However, a
number of limitations of spirometry for
the diagnosis, classification, and longitudinal monitoring of COPD are motivating the development of new COPD
measurements (5), including those derived from noninvasive imaging (6,7).
For example, thin-section multidetector computed tomography (CT) (8–11)
has been used to identify phenotypes
of both emphysema and airway disease

Advances in Knowledge
n In a small group of ex-smokers
with chronic obstructive pulmonary disease (COPD), hyperpolarized 3He MR imaging measurements showed significant
progression after 26 months,
whereas forced expiratory
volume in 1 second (FEV1) did
not significantly change.

(12–14) and depicts significant COPD
changes during relatively short periods
of time (15).
Hyperpolarized helium 3 (3He)
magnetic resonance (MR) imaging has
recently emerged as another research
method for the evaluation of COPD
(16–20). In particular, previous work
showed that the apparent diffusion
coefficient (ADC) derived from 3He
MR imaging (16,21–23) was a sensitive measurement of emphysematous
destruction (19,23,24) and airspace
size (16,17,25,26) and correlated with
pulmonary function (FEV1 and diffusing capacity of lung for carbon monoxide) (27), as well as histologic measurements of lung surface area (28).
Importantly, 3He MR imaging–derived
ADC is also age dependent (29) and
reflects differences in patient anatomic
position (30), disease severity (31), and
smoking history (32). Quantitative focal 3He MR imaging–derived ventilation
defects have also been shown in COPD
(24,32–34), and these reflect differences in subject age (35) and disease
status (20). To better understand the
potential for hyperpolarized 3He MR
imaging to provide quantitative longitudinal COPD end points, we designed a
pilot longitudinal 3He MR imaging study
of COPD. The purpose of this study
was to quantitatively evaluate a small
pilot group of ex-smokers with COPD
and healthy volunteers over the course
of approximately 2 years by using hyperpolarized 3He MR imaging.

n There was a significant inverse
correlation between changes in
3
He MR imaging–derived ventilation defect volume measurements
and FEV1.
n Hyperpolarized 3He MR imaging
is a sensitive tool for the quantitative longitudinal evaluation of
COPD.
Radiology: Volume 256: Number 1—July 2010
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Materials and Methods
Subjects
Twenty subjects were enrolled from
the general population of the local tertiary health care center, as previously
described (20). All subjects provided
written informed consent to the study
protocol, which was approved by the
local research ethics board and Health
Canada, and the study was compliant
with the Personal Information Protection and Electronic Documents Act and
the Health Insurance Portability and
Accountability Act. Subjects with COPD
were enrolled who were ex-smokers between the ages of 50–70 years and who
had a clinical diagnosis of COPD. Those
enrolled subjects with COPD were categorized according to the Global Initiative
for Chronic Obstructive Lung Disease
criteria (4) and had a smoking history
of at least 10 pack-years and had fewer
than three COPD exacerbations within
the past 12 months. Exacerbations during the follow-up period were defined
as hospitalization for COPD or as the
patient’s first-time need for antibiotic
or prednisone therapy, and these were
reported from hospital records (36)
and subject charts and were additionally verified with a telephone interview
with the subject after follow-up imaging
was completed. Subjects with COPD
were excluded during a screening visit

Published online
10.1148/radiol.10091937

Implication for Patient Care
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n In a small group of ex-smokers
with COPD, hyperpolarized 3He
MR imaging depicted significant
changes in apparent diffusion
coefficient and ventilation measurements, whereas there was no
significant change in FEV1; this
finding suggests that regional 3He
MR imaging measurements provide adequate sensitivity for
detecting COPD changes during
relatively short time periods,
before significant changes in
FEV1 can be detected.

Abbreviations:
ADC = apparent diffusion coefficient
COPD = chronic obstructive pulmonary disease
FEV1= forced expiratory volume in 1 second
VDV = ventilation defect volume
VDP = ventilation defect percentage
Author contributions:
Guarantor of integrity of entire study, G.P.; study concepts/study
design or data acquisition or data analysis/interpretation, all
authors; manuscript drafting or manuscript revision for important intellectual content, all authors; manuscript final version
approval, all authors; literature research, M.K., L.M., G.P.; clinical studies, M.K., A.W., D.G.M., G.P.; statistical analysis, M.K.,
A.W., G.P.; and manuscript editing, M.K., L.M., A.W., D.G.M., G.P.
Authors stated no financial relationship to disclose.

281

THORACIC IMAGING: Chronic Obstructive Pulmonary Disease at 3He MR Imaging

if FEV1 was greater than 3% after administration of salbutamol. Healthy volunteers were enrolled (same age range
as the subjects with COPD) who had
a smoking history of less than 1 packyear with no smoking in the previous 25
years and no history of previous chronic
or current respiratory disease. All tests
and imaging were performed at baseline and at 26 months 6 2 (standard
deviation).

Pulmonary Function Tests
Spirometry was performed by using a
spirometer (ndd EasyOne; Medizintechnik, Zurich, Switzerland) to report
FEV1 and forced vital capacity with a
minimum of three acceptable spirometry maneuvers; the best FEV1 and
forced vital capacity were selected for
analysis according to American Thoracic Society guidelines (37). Wholebody plethysmography was performed
by using a stand-alone body plethysmograph (Elite Series; MedGraphics,
St Paul, Minn) for the measurement of
total lung capacity, inspiratory capacity,
residual volume, and functional residual
capacity.
MR Imaging
Subjects were screened for MR imaging and coil compatibility (inner diameter of elliptical coil = 50 cm) prior
to imaging, and digital pulse oximetry
was used to monitor arterial blood
oxygenation levels during breath-hold
MR imaging. A turnkey, spin-exchange
polarizer system (HeliSpin; GE Healthcare, Durham, NC) was used to polarize 3He gas to 30%–40%, as previously
described (38). Doses of hyperpolarized 3He gas (5 mL per kilogram of
body weight) were administered in
1-L plastic bags (Tedlar; Jensen Inert
Products, Coral Springs, Fla) and were
diluted with ultrahigh purity, medicalgrade nitrogen (Spectra Gases, Alpha,
NJ). Polarization of the diluted dose
was quantified at a polarimetry station
(GE Healthcare, Durham, NC) immediately prior to 3He gas administration
to subject.
MR imaging was performed with a
whole-body 3.0-T MR imaging system
(Excite 12.0; GE Healthcare, Milwaukee,
282
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Wis) with broadband imaging capability, as previously described (33). All
3
He MR imaging was performed with a
whole-body gradient set with a maximum gradient amplitude of 1.94 G/cm
and a single-channel, rigid elliptical
transmit-receive chest coil (RAPID Biomedical, Würzburg, Germany). The basis frequency of the coil was 97.3 MHz,
and excitation power was 3.2 kW by
using a radiofrequency power amplifier
(AMT 3T90; GE Healthcare, Milwaukee,
Wis).
Coronal two-dimensional multiplesection hydrogen 1 (1H) images were
acquired prior to 3He MR imaging, with
subjects imaged during 1-L breath hold
of the 4He-N2 mixture from a starting
point of functional residual capacity by
using a whole-body radiofrequency coil
and a proton fast spoiled-gradient-echo
sequence (16-second total data acquisition; repetition time msec/echo time
msec, 4.7/1.2; flip angle, 30°; field of
view, 40 3 40 cm; matrix, 256 3 256; 14
sections; 15-mm section thickness; 0-cm
intersection gap). For diffusion-weighted
imaging, coronal multisection images
were obtained by using a fast gradientecho method with centric k-space sampling. Two interleaved images (14-second
total data acquisition; 7.6/3.7; flip angle,
8°; field of view, 40 3 40 cm; matrix,
128 3 128; seven sections; 30-mm section thickness), with and without additional diffusion sensitization (maximum
gradient amplitude = 1.94 G/cm, rise and
fall time = 0.5 msec, gradient duration =
0.46 msec, diffusion time = 1.46 msec,
b value = 1.6 sec/cm2), were acquired. For
ventilation, or spin-density, imaging, coronal multisection images were obtained
by using the same 3He coil (14-second
total data acquisition; 4.3/1.4; flip angle,
7°; bandwidth, 31.25 kHz; field of view,
40 3 40 cm; matrix, 128 3 128; 14 sections; 15-mm section thickness; 0-cm
intersection gap) and multisection twodimensional simultaneous acquisition
of a ventilation image (no T1-weighted
sensitization) and a T1-weighted image. Only images without T1-weighting
were used for ventilation analysis in this
study. All imaging was completed within
approximately 7–10 minutes of subjects
first lying in the imager.

Image Analysis
The signal-to-noise ratio for all images
acquired was determined by calculating the mean pixel value within a 10 3
10-voxel region of interest for four representative regions of interest within
the lung parenchyma and dividing by
the standard deviation of the mean pixel
values for noise inside a region of interest of the same size at the corners of the
image where there was no lung structure. Signal-to-noise ratio was determined for each section and then was averaged to obtain a single signal-to-noise
ratio for each subject and time point.
Images were analyzed in a controlled
image visualization environment with
room lighting levels equivalently established for all image analysis sessions.
ADC maps were processed by using in-house software programmed in
the interactive data language Virtual
Machine platform (Research Systems,
Denver, Colo) as previously described
(33) with a b value of 1.6 sec/cm2. Spindensity images were examined for analysis
of ventilation defects in all coronal sections by two expert observers (M.K. and
L.M.) blinded to subject identity, disease
status, and time point, as well as the other
observer’s measurements. As previously
described (39), a ventilation defect was
identified by each observer independently as any lung region of diminished
signal intensity but not those areas of
signal loss associated with the pulmonary vascular structures, heart, hilum,
and mediastinum. Images were reviewed
such that 3He and 1H images were visible
on a digital workstation monitor system
(consisting of identical 19-inch flat panel
monitors). Manual segmentation of ventilation defects was performed by using
custom-designed image visualization
software that also provided a method for
two-dimensional rigid single-point image
registration (1H and 3He sections) based
on the carina, which facilitated the manual segmentation of ventilation defects
in all sections. Ventilation defect volume
(VDV) and thoracic cavity volume were
recorded following manual segmentation of 3He and 1H images, respectively,
and were used to calculate ventilation
defect percentage (VDP) (16,25,26,40).
VDV was derived from the manually
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Table 1
Subject Demographic Characteristics in Ex-Smokers with COPD and Never-Smokers
Healthy Never-Smokers (n = 5)
Parameter
Age (y)
No. of men
Body mass index (kg/m2)
FEV1 (L)
FEV1 (percentage predicted)
FEV1/FVC ratio
Inspiratory capacity (%)
Reserve volume (%)
Functional residual capacity (%)
Total lung capacity (%)

Ex-Smokers with COPD (n = 15)

Baseline

Follow-up

Baseline

Follow-up

69 6 6 (58–74)
2
25 6 2 (24–29)
2.77 6 1.01
110 6 23
77 6 4
106 6 18
95 6 15
101 6 12
105 6 12

72 6 6 (61–76)
2
25 6 2 (23–28)
2.62 6 0.93
107 6 23
78 6 15
...
...
...
...

68 6 6 (59–75)
8
28 6 5 (19–38)
1.51 6 0.63
53 6 15
45 6 14
88 6 23
157 6 48
145 6 65
109 6 17

70 6 5 (61–77)
8
27 6 5 (18–37)
1.43 6 0.56
52 6 15
49 6 16
82 6 22
132 6 33
131 6 33
105 6 10

Note.—Unless otherwise indicated, data are means 6 standard deviations, with ranges in parentheses.

segmented ventilation defect area for
each section, and this was multiplied by
the section thickness; VDV for all sections was summed to obtain whole-lung
VDV. For the center section, which was
the middle section acquired that clearly
showed the carina and two main bronchi, VDV was also manually segmented
and reported. In addition, whole-lung
and center-section measurements were
recorded for thoracic cavity volume for
calculation of whole-lung and centersection VDP, as well as for ADC.

Statistical Methods
For 3He MR imaging ventilation measurements, observer reproducibility
was evaluated for two observers by using the interclass correlation coefficient, coefficient of variation, and linear regression (r2) by using software
(SPSS, version 16.00; SPSS, Chicago,
Ill). Comparison of baseline and follow-up
means was performed by using a Wilcoxon matched-pairs two-tailed t test
(SPSS, version 16.00). The relationship
between changes in 3He MR imaging
measurements and changes in pulmonary function measurements at follow-up
was determined by using linear regression and Spearman correlation
coefficients by using software (Prism,
version 4.00; GraphPad Software, San
Diego, Calif). The relationship between the changes in 3He MR imaging–
derived VDV and smoking history was
determined by using linear regression
Radiology: Volume 256: Number 1—July 2010

n

and Spearman correlation coefficients
(Prism, version 4.00). The HolmBonferroni correction (41) was used for
multiple paired t tests and all correlations. The Holm-Bonferroni–adjusted
P values were determined by ordering
P values from smallest to largest, with
the smallest P value multiplied by k,
where k is the number of hypotheses
to be tested. If the resulting modified
P value was less than a (type I error
rate), the hypothesis was rejected. The
next smallest P value was then multiplied by k 2 1, and the new modified
P value was compared with a. This
process was repeated until the modified P value could not be rejected. In all
statistical analyses, results were considered significant when the probability of
making a type I error was less than 5%
(P , .05). A retrospective sample size
(n) calculation was performed to detect
a significant change (d) in FEV1 with a
equal to .05 and power b equal to .80
and where SD is standard deviation; accordingly, Za was 1.96 and Zb was 0.2,
and n was calculated according to the
following equation (42):
2

n

2 Z a  Zb SD 2
d2

.

Results
Demographic characteristics are provided
in Table 1. All subjects with COPD

radiology.rsna.org

were nonsmokers at baseline with a
mean smoking history of 47 pack-years
6 22 (range, 11–85 pack-years) and
mean years of not smoking at baseline
of 11 years 6 10 (range, 10 weeks to
34 years). Three subjects experienced
a single COPD exacerbation during the
follow-up period.
Table 2 shows mean and median
whole-lung and center-section hyperpolarized 3He MR imaging measurements
for healthy never-smokers and subjects
with COPD. The absolute change and
annualized rates of change of FEV1 and
hyperpolarized 3He MR imaging measurements for subjects with COPD are
provided in Table 3. For ADC, annualized rate of change for ex-smokers with
COPD was 0.01 cm2/sec and that for
never-smokers was 0.002 cm2/sec. There
was no significant association between
the changes in image signal-to-noise ratio and the changes in ADC (r = 20.51,
P = .12) and VDV (r = 20.17, P = .55).
Interobserver reproducibility of 3He MR
imaging–derived VDV was previously
evaluated for three observers, and this
was the same as intraobserver variability
(coefficient of variation = 10%, unpublished results). For two observers, interobserver reproducibility was assessed for
whole-lung VDV (interclass correlation coefficient = 0.93, coefficient of variation =
38%, and r2 = 0.84 [P , .0001]) and
whole-lung VDP (interclass correlation
coefficient = 0.91, coefficient of variation = 43%, and r2 = 0.81 [P , .0001]).
283

THORACIC IMAGING: Chronic Obstructive Pulmonary Disease at 3He MR Imaging

Kirby et al

Table 2
Helium 3 MR Imaging–derived ADC and Ventilation Defect Measurements at Baseline and Follow-up
Healthy Never-Smokers (n = 5)
Parameter
2

Whole-lung ADC (cm /sec)
Center-section ADC (cm2/sec)
Whole-lung VDV (L)
Center-section VDV (L)
Whole-lung VDP (%)
Center-section VDP (%)

Ex-Smokers with COPD (n = 15)

Baseline

Follow-up

Baseline

Follow-up

0.27 (0.25) [0.02]
0.28 (0.27) [0.02]
0.023 (0.006) [0.04]
0.003 (0.000) [0.005]
0.5 (0.2) [0.9]
0.6 (0.2) [0.9]

0.29 (0.29) [0.03]
0.28 (0.30) [0.03]
0.020 (0.017) [0.02]
0.002 (0.001) [0.002]
0.5 (0.5) [0.4]
0.4 (0.2) [0.4]

0.43 (0.45) [0.08]
0.44 (0.45) [0.09]
0.52 (0.24) [0.54]
0.056 (0.023) [0.053]
9 (6) [9]
9 (11) [13]

0.46 (0.46) [0.07]
0.47 (0.46) [0.08]
0.92 (0.77) [0.93]
0.11 (0.11) [0.11]
16 (15) [14]
16 (16) [22]

Note.—Data are means, with medians in parentheses and standard deviations in brackets.

Figure E1 (online) shows the relationship between ventilation defect measurements (whole-lung VDV [r2 = 0.84, P ,
.0001] and whole-lung VDP [r2 = 0.81,
P , .0001]) for observer 1 and 2. The
change at follow-up for observer 1 and
2 were significantly correlated for wholelung VDV (r2 = 0.51, P = .0004) and
whole-lung VDP (r2 = 0.39, P = .007).
The change in whole-lung VDV and
whole-lung VDP for each observer and
the mean for both observers is provided
in Table E1 (online), and throughout the
main body of the article, a single observer’s results are described. Table E2 (online) shows a subject listing of baseline
and follow-up pulmonary function and
3
He MR imaging measurements.
Wilcoxon matched-pairs two-tailed
t tests indicated that all 3He MR imaging
measurements were significantly different at follow-up for subjects with COPD.
There was no significant change observed in FEV1 (percentage predicted)
for subjects with COPD at follow-up.
For healthy never-smokers, there was
no detectable change in any pulmonary
function or imaging measurement. The
changes detected in the ex-smokers with
COPD were significantly different than
the changes measured in the healthy volunteers for whole-lung VDV (P = .04)
and whole-lung VDP (P = .01) but were
not significantly different for whole-lung
ADC (P = .96) or FEV1 (P = .21).
Figure 1 shows ventilation images,
ADC maps, and ADC histograms for two
representative healthy never-smokers at
baseline and follow-up. Figure 2 shows
ventilation images, ADC maps, and
ADC histograms for two representative
284

Table 3
Annualized Change in Pulmonary Function and 3He MR Imaging Measurements in
Subjects with COPD at Follow-up
Parameter
FEV1 (percentage predicted)
Whole-lung ADC (cm2/sec)
Center-section ADC (cm2/sec)
Whole-lung VDV (L)
Center-section VDV (L)
Whole-lung VDP (%)
Center-section VDP (%)

Absolute Change

Annualized Rate of Change

P Value*

21
0.02
0.03
0.4
0.05
7
7

20.4
0.01
0.01
0.20
0.03
4
3

.97 (.97)
.01 (.02)
.004 (.02)
.007 (.03)
.003 (.02)
.0009 (.006)
.01 (.03)

* Data are P values determined with Wilcoxon matched-pairs two-tailed t tests, with Holm-Bonferroni–adjusted P values in
parentheses.

subjects with COPD at baseline and
follow-up.
Table 4 shows Spearman correlation coefficients for the relationship
between the changes in FEV1 (absolute
and percentage predicted) and those in
3
He MR imaging–derived ADC, VDV,
and VDP for subjects with COPD. As
shown in Figure 3, the change in FEV1
(absolute) showed a significant negative
association with the change in centersection VDV (r = 20.70, P = .02) and
center-section VDP (r = 20.70, P =
.03) but not with the change in ADC.
Thoracic cavity volume was calculated
for all subjects from 1H MR imaging of the thoracic cavity, and for all
subjects, the change in thoracic cavity volume was significantly correlated
with the change in total lung capacity
measured by using plethysmography (r =
0.81, P = .001). Figure 4 shows the relationships between smoking history
of patients with COPD (pack-years
smoking) and the changes in 3He MR

imaging–derived VDV and FEV1. There
was no significant correlation between
pack-years smoking and the change in
FEV1 (r = 0.05, P = .83), and the relationship between pack-years smoking
and whole-lung VDV was moderate, but
once corrected for multiple tests, this
relationship was on the threshold of
significance (whole-lung VDV [r = 0.52;
P = .02, uncorrected; P = .06, HolmBonferroni corrected]).

Discussion
Several observations were made in this
small longitudinal pilot study. First, we
observed that mean 3He MR imaging–
derived ADC, VDV, and VDP significantly increased during the 26-month
follow-up period in 15 ex-smokers
with COPD, whereas pulmonary function measurements did not significantly
change during the same time period.
Because of the previously reported and
pioneering epidemiologic findings of

radiology.rsna.org
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Figure 1

Figure 1: Representative hyperpolarized 3He MR data at baseline (top) and follow-up (bottom) in healthy never-smokers. Left: A, Ventilation
image, B, ADC map, and, C, ADC histogram in 58-year-old man (subject 1001). Right: A, Ventilation image, B, ADC map, and, C, ADC histogram
in 73-year-old man (subject 1007).

Figure 2

Figure 2: Representative hyperpolarized 3He MR data show VDV and ADC changes during follow-up in COPD. Left: A, Ventilation image, B,
ADC map, and, C, and ADC histogram in 75-year-old man with stage III COPD (subject 3004). Right: A, Ventilation image, B, ADC map, and, C,
ADC histogram in 61-year-old man with stage II COPD (subject 2009). Top = baseline, bottom = follow-up.

Radiology: Volume 256: Number 1—July 2010
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Table 4
Relationship between FEV1 Changes and 3He MR Imaging Measurement Changes for
Subjects with COPD over the Course of Time
Parameter
2

Whole-lung ADC (cm /sec)
Center-section ADC (cm2/sec)
Whole-lung VDV (L)
Center-section VDV (L)
Whole-lung VDP (%)
Center-section VDP (%)

FEV1 (L)

FEV1 (Percentage Predicted)

20.02 (.93) [.93]
20.06 (.84) [..99]
20.56 (.03) [.09]
20.70 (.003) [.02]
20.60 (.02) [.08]
20.70 (.005) [.03]

0.17 (.56) [..99]
0.15 (.60) [.60]
20.53 (.04) [.12]
20.67 (.007) [.04]
20.55 (.03) [.12]
20.70 (.005) [.03]

Note.—Data are Spearman correlation coefficients, with P values in parentheses and Holm-Bonferroni–adjusted P values in
brackets.

Figure 3

Figure 3: Scatterplots show the relationship
between changes in FEV1 and changes in (a)
center-section (CS) VDP, (b) center-section VDV,
and (c) whole-lung (WL) ADC. Dotted lines = 95%
confidence intervals for the regressions. Changes
in FEV1 showed a significant negative correlation
with changes in center-section VDV (r = 20.70,
P = .02) and center-section VDP (r = 20.70,
P = .03). Changes in FEV1 showed no significant
correlation with changes in whole-lung ADC.

Fletcher and Peto (3), as well as the
more recent findings of a tiotropium intervention trial (43), we were not surprised to find that in ex-smokers with
COPD, FEV1 did not significantly change.
Indeed, this study was not powered to
detect such changes in FEV1 during an
approximately 2-year time frame; a retrospective power analysis showed that
a sample size of approximately 1000
patients with COPD and 1000 healthy
volunteers would be required to detect
significant change in FEV1 in this study.
Unlike the Fletcher curve prediction
that longitudinal changes in hyperpolarized 3He MR imaging measurements
286

in ex-smokers with COPD would be
similar to those observed in healthy
never-smokers, we observed an annualized rate of change in 3He MR imaging–derived ADC of 0.01 cm2/sec—an
order of magnitude greater than the
rate previously reported (0.001 cm2/sec)
for healthy nonsmokers in a crosssectional multicenter study at 1.5 T (29)
and for the healthy never-smokers reported in this study (0.002 cm2/sec).
In addition, we observed no significant
change in 3He MR imaging–derived
ADC, ventilation defect measurements,
or pulmonary function measurements
for healthy never-smokers at follow-up.

These preliminary longitudinal findings
suggest that regional disease markers derived at noninvasive imaging can
be used in a small number of subjects
with COPD during short time periods to quantitatively detect significant
changes.
We also showed that the change in
3
He MR imaging–derived VDV and VDP
indicated a significant inverse correlation with the change in FEV1, whereas
the change in ADC showed no such relationship. This result suggests that 3He
MR imaging–derived ventilation defect
measurements may be more predictive of airflow limitation than 3He MR
imaging–derived ADC, which necessitates further testing of this hypothesis.
Although we observed statistically significant improvements in FEV1 of less
than 20 mL in five subjects with COPD,
we did not observe a corresponding improvement in 3He MR imaging–derived
measurements during this time period.
On the contrary, for these five subjects,
we observed a statistically significant
increase in 3He MR imaging–derived
ADC (P = .02) and no change in ventilation measurements. We believe this
discordant finding highlights the sensitivity of using both ventilation and ADC
measurements in detecting disease
changes in COPD. In a related finding,
Ohara and colleagues (15) showed a
significant inverse correlation between
annual changes in FEV1 and CT measurement of wall area percentage (a
surrogate of airway wall thickness),
and, similar to our results, there was
no significant relationship between the
change in FEV1 and emphysema (percentage of low attenuation areas). For
five of 15 subjects with COPD evaluated
in this pilot analysis, both imaging and
spirometry results suggested disease
progression. This finding generates a
number of hypotheses to test in larger
or longer imaging studies of COPD progression that will evaluate the relationship between exacerbations, treatment
changes, and changes in quality of life
with imaging and pulmonary function
measurements. Future COPD studies
that include hyperpolarized 3He MR imaging will likely focus on a critical balance between longitudinal time frame
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Figure 4

Figure 4: Scatterplot shows the relationship between smoking history and change in wholelung (WL) VDV (r = 0.52; P = .02; P = .06, Holm-Bonferroni corrected) and change in FEV1
(percentage predicted) (r = 0.05, P = .83).

and finite numbers of subjects because
of the relative complexity of these studies and the prediction for increased
costs and decreased availability of 3He
gas for clinical research (44). Nevertheless, the preliminary findings of this pilot hyperpolarized 3He MR imaging longitudinal study provide clear guidance
for future COPD imaging studies on
established and emerging imaging tools
such as optical coherence tomography
(45), oxygen-enhanced and proton MR
imaging methods (46,47), and hyperpolarized xenon 129 MR imaging.
Finally, we showed in an exploratory
analysis, the potential relationship between smoking history and changes
in 3He MR imaging–derived VDV but
not with changes in FEV1. Previous
cross-sectional studies suggest ongoing inflammation in ex-smokers with
COPD (3,29) and that smoking history correlated with current inflammatory markers such as eosinophils (48)
and vascular endothelial growth factor
(49), which supports the hypothesis
that there is a predictive relationship
between pack-years and inflammation
after smoking cessation. The results of
this exploratory analysis of 3He MR imaging changes and smoking history generate important hypotheses that future
studies should explore in more detail.
Radiology: Volume 256: Number 1—July 2010
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Although this pilot study showed
significant increases in 3He MR imaging–
derived measurements in just more
than 2 years, we must acknowledge a
number of specific limitations of our approach. We recognize that the relatively
small group of subjects with COPD and
healthy never-smokers who were evaluated and the relatively short period of
follow-up compared with other COPD
longitudinal studies (5) certainly limited the applicability of our results. The
small sample size necessitates cautious
interpretation of the results, as well as
the future requirement for larger studies to test the hypotheses generated.
For example, because of the small number of healthy volunteers and subjects
with COPD evaluated, significant differences were not detected for pulmonary
function measurements in either group.
In addition, although we have previously
demonstrated that ventilation defects
are highly reproducible (20), the lack
of longitudinal information regarding
the variability of ventilation defects necessitates that the findings of this study
be interpreted with caution.
Although this pilot study showed
that ex-smokers with COPD differed
from never-smokers, it was not designed
to show the relationship between the
significant imaging changes and more-
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established clinical measurements of
COPD worsening. To make the important conclusion that 3He MR imaging
measurements are specifically related to
clinical measurements of COPD worsening, future work in longer or larger
studies must show that the detected
3
He MR imaging changes occurred in
patients who had measureable clinical changes. Nevertheless, the results
suggest that 3He MR imaging provides
a sensitive method for the detection of
structural and functional changes of the
lung that accompany COPD longitudinally. In the future, larger studies that
directly compare 3He MR imaging and
other well-established clinical measurements of COPD progression will be required to better understand the relationship between 3He MR imaging–derived
measurements and other changes that
occur in COPD over the course of time.
In addition, a comparison of ex-smokers
with COPD, healthy smokers, and current smokers with COPD may help to
establish and directly compare rates
of structural and functional decline of
the lung. It will also be critical to track
patient exacerbations and changes in
treatment during longer time periods to
probe potential treatment effects with
imaging. We also acknowledge that for
this pilot study, we limited the COPD
cohort to those with minimal FEV1 reversibility, although clearly many subjects with COPD have varying degrees
of FEV1 reversibility, which necessitates
further work in such patients.
CT images were not prospectively
acquired for this study; and therefore,
our results cannot be directly compared
with more-established CT measurements such as percentage of low attenuation areas (measurement of the extent
of emphysema) or wall area percentage
(measurement of airway wall thickness).
Clearly, a direct comparison of CT
and hyperpolarized 3He MR imaging–
derived measurements in the same
subjects will allow for a better understanding of differences in measurement
sensitivity these imaging modalities
provide.
A previous study (32) has shown significant correlation between ADC and
the measurement of diffusing capacity
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of lung for carbon monoxide. A direct
comparison in this study would have
provided another quantitative measure
of global emphysematous changes in
these subjects. While Woods and colleagues (28) have previously shown
the significant correlation between 3He
MR imaging–derived ADC and histologic measurements of emphysema,
we have not yet determined the underlying disease that results in the 3He
MR imaging–derived ventilation defects
we observe, which may be a result of
small airway occlusion, mucous plugs,
airway wall thickening and inflammation, or bullous disease. Related to this
is the fact that there is important information in regions of intermediate
signal intensity and in both hyper- and
hypointense regions that has not yet
been quantitatively or spatially exploited. The development and validation of
3
He MR image analysis techniques that
quantify heterogeneous signal intensity
information are required in the future
to fully characterize the important ventilation information contained on the
image. Whether regions of diminished
ventilation and emphysema develop independently and the extent to which
one leads to the other cannot be ascertained by results of this preliminary
longitudinal study and has yet to be
determined in other longitudinal imaging studies. Importantly, however, our
group previously described the high
reproducibility of 3He MR imaging–
derived ventilation defects in COPD (20),
suggesting that the significant changes
measured in this study may be because
of changes in lung morphology or
function and not because of the variability of the imaging or measurement
technique or because of short-term
changes in small airway diameter or
patency.
In summary, in this small pilot study
of ex-smokers with COPD, by using 3He
MR imaging we detected significant
lung changes that occurred during a
relatively short time period, perhaps
before FEV1 changes could be detected
or perhaps because such longitudinal
changes occurred within the FEV1 silent
zones, where disease might have accumulated without detection.
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